Sermorelin

Scientific Overview, Mechanism, Clinical Use and Evidence

Scientific Overview

Sermorelin is a synthetic GHRH (1–29) analog that stimulates physiologic growth hormone secretion. Unlike exogenous GH therapy, it supports endogenous pulsatile release, maintaining feedback regulation of the hypothalamic-pituitary axis. In peptide-based hormone optimization frameworks, Sermorelin is positioned as a regulatory modulator of the GH–IGF-1 axis.

Mechanism of Action

Sermorelin binds to pituitary GHRH receptors, promoting:

• Pulsatile GH release
• Increased hepatic IGF-1 production
• Enhanced protein synthesis
• Improved lipolysis and metabolic balance

Biological and Clinical Effects

Clinical findings show elevation of GH and IGF-1 levels, improvements in body composition markers, and preservation of pituitary integrity. Functional medicine perspectives emphasize its role in restoring physiologic signaling rather than replacing hormones.

Time of Use / Treatment Duration

Initial evaluation period: 3–6 months. Long-term endocrine modulation protocols may extend 6–12 months. Periodic reassessment of IGF-1 every 8–12 weeks recommended. Continuous indefinite use should be clinically justified.

Safety, Tolerability, and Precautions

Potential effects include injection site reactions, headache, and flushing. Contraindicated in active malignancy and uncontrolled endocrine disorders.

Detailed References

Thorner MO, et al. (1986). Growth hormone-releasing hormone stimulates growth hormone secretion in man. Journal of Clinical Investigation, 78(1):55–60.

FDA. Sermorelin acetate historical approval information (Geref®).

Biller BMK, et al. (2000). Growth hormone-releasing hormone analog therapy in adults with GH deficiency. Journal of Clinical Endocrinology & Metabolism, 85(9):3453–3460.

Vance ML. (1990). The role of growth hormone-releasing hormone in physiology and therapy. Endocrine Reviews, 11(3):353–377.

LaValle J. The Complete Guide to Peptides. GH axis modulation, endocrine resilience, and physiologic hormone signaling.

Posology (Clinical Practice–Oriented)

Common adult dosing regimens:

• 0.2 mg – 0.5 mg subcutaneously at bedtime
• Once daily, 5–7 days per week

Dosing may be adjusted based on:

• IGF-1 level
• Clinical symptoms
• Age and body composition

Pediatric GH deficiency dosing follows approved labeling.

Clinical Practice Framing

Sermorelin is best framed as a physiologic endocrine modulator, integrated with sleep optimization, resistance training, and metabolic health strategies.

The peptides described in this material are intended strictly for research purposes only. They are not approved for human or veterinary use, clinical application, diagnosis, treatment, or prevention of any disease.

Any research involving these compounds must be conducted in compliance with applicable laws and regulations in the country where the research is performed, including prior approval by a duly constituted Ethics Committee or Institutional Review Board (IRB), where required.

RegenPept acts solely as a supplier of research-grade materials and assumes no responsibility or liability for the design, conduct, regulatory compliance, interpretation, or outcomes of any research involving these products.

Any dosage, administration protocols, or related information contained in this material are derived from publicly available scientific literature and are provided strictly for informational purposes. Such information does not constitute medical advice, therapeutic recommendation, or endorsement of any specific use by RegenPept.